IP Library Patent Application 17066134
Patent Application
App. No. 17/066,134

SPHERICAL NUCLEIC ACID-BASED CONSTRUCTS AS IMMUNOSTIMULATORY AGENTS FOR PROPHYLACTIC AND THERAPEUTIC USE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/066,134
Abstract

Aspects of the invention relate to spherical nucleic acid-based constructs and related methods and compositions thereof. The compositions of the invention are useful for activating agonists of nucleic acid interacting complexes, such as TLRs, stimulating an immune response, and treating diseases such as infectious disease, cancer, allergies, allergic diseases, and autoimmune disease

Claims (25)

1 . A nanoscale construct comprising:

a corona comprised of an exterior shell composed of nucleic acid molecules arranged in a geometrical position and forming a spherical shape around a nanoparticle core, wherein the nucleic acid molecules are CpG oligonucleotides, wherein the nanoscale construct is about 1 nm to about 40 nm in diameter, and wherein the nanoparticle core at the center of the corona is not metallic.

2 . The nanoscale construct of claim 1 , wherein the surface density of the nucleic acid molecules is at least 0.3 pmol/cm 2 .

3 . The nanoscale construct of claim 1 , wherein the nucleic acid molecules comprise a spacer.

4 . The nanoscale construct of claim 3 , wherein the spacer consists of oligoethylene.

5 . The nanoscale construct of claim 1 , wherein the nanoparticle core at the center of the corona is hollow.

6 . The nanoscale construct of claim 1 , wherein the nanoscale construct is degradable.

7 . The nanoscale construct of claim 1 , wherein the CpG oligonucleotide has a modified backbone.

8 . The nanoscale construct of claim 1 , further comprising an antigen.

9 . A method for delivering a therapeutic agent to a cell comprising delivering the nanoscale construct of claim 1 to the cell.

10 . A method of treating a subject, comprising administering to the subject a nanoscale construct in an effective amount to stimulate an immune response, wherein the nanoscale construct comprises a corona having an exterior shell composed of nucleic acid molecules arranged in a geometrical position and forming a spherical shape around a nanoparticle core, wherein the nucleic acid molecules are CpG oligonucleotides, and wherein the nanoscale construct is about 1 nm to about 40 nm in [[mean]] diameter, and wherein the nanoparticle core at the center of the corona is not metallic.

11 . The method of claim 10 , wherein the subject has an infectious disease.

12 . The method of claim 10 , wherein the subject has cancer.

13 . A method for activating a toll-like receptor (TLR), the method comprising delivering to a cell a nanoscale construct, wherein the nanoscale construct comprises a corona having an exterior shell composed of nucleic acid molecules arranged in a geometrical position and forming a spherical shape around a nanoparticle core, wherein the nucleic acid molecules are CpG oligonucleotides, wherein the nanoscale construct is about 1 nm to about 40 nm in diameter, and wherein the nanoparticle core at the center of the corona is not metallic.

14 . The method of claim 13 , wherein the cell is in vivo.

15 . The method of claim 14 , wherein the nanoscale construct is administered to a subject having cancer.

16 . The nanoscale construct of claim 4 , wherein the oligoethylene is hexaethylene glycol.

17 . The nanoscale construct of claim 4 , wherein the spacer consists of two or three hexaethylene glycols.

18 . The nanoscale construct of claim 3 , wherein the spacer does not comprise an oligonucleotide. (New) The nanoscale construct of claim 1 , wherein the CpG oligonucleotide has a phosphorothioate (PS) backbone.

20 . A nucleic acid molecule comprising a CpG oligonucleotide having the nucleotide sequence of SEQ ID NO: 30, wherein the nucleic acid molecule comprises a spacer consisting of oligoethylene.

21 . The nucleic acid molecule of claim 20 , wherein the CpG oligonucleotide has a phosphorothioate (PS) backbone.

22 . The nucleic acid molecule of claim 20 , wherein the oligoethylene is hexaethylene glycol.

23 . The nucleic acid molecule of claim 20 , wherein the spacer consists of two or three hexaethylene glycols.

24 . A plurality of nanoscale constructs, each nanoscale construct comprising:

a corona comprised of an exterior shell composed of nucleic acid molecules arranged in a geometrical position and forming a spherical shape around a nanoparticle core, wherein the nucleic acid molecules are CpG oligonucleotides, wherein the nanoscale constructs have a mean diameter of about 1 nm to about 40 nm, and wherein the nanoparticle core at the center of the corona is not metallic.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2024
From: EXICURE, INC.
To: FLASHPOINT THERAPEUTICS, INC.
Reel/Frame 068971/0168 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2024
From: EXICURE, INC.
To: FLASHPOINT THERAPEUTICS, INC.
Reel/Frame 069171/0490 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2023
From: EXICURE, INC.
To: EXICURE OPERATING COMPANY
Reel/Frame 064838/0134 →
CHANGE OF NAME Recorded Aug 7, 2023
From: MAX-1 ACQUISITION CORPORATION
To: EXICURE, INC.
Reel/Frame 064834/0400 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2021
From: RADOVIC-MORENO, ALEKSANDAR FILIP; MADER, CHRISTOPHER C.; NALLAGATLA, SUBBARAO; HASAN, WAREFTA; LOVE, AARON; GRYAZNOV, SERGEI
To: EXICURE, INC.
Reel/Frame 054916/0888 →